Skip to main content
Erschienen in: Medical Oncology 8/2014

01.08.2014 | Short Communication

Analysis of V600E BRAF and D816V KIT mutations in systemic mastocytosis

verfasst von: H. Hägglund, B. Sander, A. Ahmadi, T. Gülen, G. Nilsson

Erschienen in: Medical Oncology | Ausgabe 8/2014

Einloggen, um Zugang zu erhalten

Abstract

Most patients with systemic mastocytosis (SM) carry a D816 V KIT mutation causing a ligand-independent activation of the receptor. Down-stream of KIT is several components known to be mutated in different malignancies. RAF is among the most frequently mutated kinases, where BRAF V600E mutation occurs in most hairy cell leukemias (HCL) and half of malignant melanomas. We investigated BRAF mutations in 36 subjects with different forms of SM, but could not detect BRAF mutation in any of the cases, not even in the mast cell lineage of a patient with V600E BRAF-positive HCL. Thus, although BRAF is commonly mutated it appears not to be present in SM.
Literatur
2.
Zurück zum Zitat Valent P, Akin C, Escribano L, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest. 2007;37:435–53.PubMedCrossRef Valent P, Akin C, Escribano L, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest. 2007;37:435–53.PubMedCrossRef
3.
Zurück zum Zitat Valent P, Sperr WR, Akin C. How I treat patients with advanced systemic mastocytosis. Blood. 2010;116:5812–7.PubMedCrossRef Valent P, Sperr WR, Akin C. How I treat patients with advanced systemic mastocytosis. Blood. 2010;116:5812–7.PubMedCrossRef
4.
Zurück zum Zitat Gotlib J, Kluin-Nelemans H, George T, et al. Durabel responses and improved quality of life with midostaurin (PKC412) in advanced systemic mastocytosis (SM): Updated stage 1 results of the global D2201 trial. Abstract 106, 55th American Society of Hemtology meeting. 2013. Gotlib J, Kluin-Nelemans H, George T, et al. Durabel responses and improved quality of life with midostaurin (PKC412) in advanced systemic mastocytosis (SM): Updated stage 1 results of the global D2201 trial. Abstract 106, 55th American Society of Hemtology meeting. 2013.
5.
Zurück zum Zitat Schwaab J, Schnittger S, Sotlar K, et al. Comprehensive mutational profiling in advanced systemic mastocytosis. Blood. 2013;122:2460–6.PubMedCrossRef Schwaab J, Schnittger S, Sotlar K, et al. Comprehensive mutational profiling in advanced systemic mastocytosis. Blood. 2013;122:2460–6.PubMedCrossRef
6.
Zurück zum Zitat Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–54.PubMedCrossRef Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–54.PubMedCrossRef
8.
Zurück zum Zitat Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353:2135–47.PubMedCrossRef Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353:2135–47.PubMedCrossRef
9.
Zurück zum Zitat Pardanani A, Tefferi A. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011;365: 961; author reply -2. Pardanani A, Tefferi A. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011;365: 961; author reply -2.
10.
Zurück zum Zitat Gülen T, Sander B, Nilsson G, Palmblad J, Sotlar K, Horny HP, Hagglund H. Systemic mastocytosis: progressive evolution of an occult disease into fatal mast cell leukemia: unique findings on an unusual hematological neoplasm. Med Oncol. 2012;29:3540–6.PubMedCrossRef Gülen T, Sander B, Nilsson G, Palmblad J, Sotlar K, Horny HP, Hagglund H. Systemic mastocytosis: progressive evolution of an occult disease into fatal mast cell leukemia: unique findings on an unusual hematological neoplasm. Med Oncol. 2012;29:3540–6.PubMedCrossRef
11.
Zurück zum Zitat Hägglund H, Sander B, Gülen T, Lindelof B, Nilsson G. Increased risk of malignant melanoma in patients with systemic mastocytosis? Acta Derm Venereol. 2014; doi:10.2340/00015555-1788. Hägglund H, Sander B, Gülen T, Lindelof B, Nilsson G. Increased risk of malignant melanoma in patients with systemic mastocytosis? Acta Derm Venereol. 2014; doi:10.​2340/​00015555-1788.
12.
Zurück zum Zitat Sotlar K, Escribano L, Landt O, et al. One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes. Am J Pathol. 2003;162:737–46.PubMedCentralPubMedCrossRef Sotlar K, Escribano L, Landt O, et al. One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes. Am J Pathol. 2003;162:737–46.PubMedCentralPubMedCrossRef
Metadaten
Titel
Analysis of V600E BRAF and D816V KIT mutations in systemic mastocytosis
verfasst von
H. Hägglund
B. Sander
A. Ahmadi
T. Gülen
G. Nilsson
Publikationsdatum
01.08.2014
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 8/2014
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-014-0123-4

Weitere Artikel der Ausgabe 8/2014

Medical Oncology 8/2014 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.